Oxidative Stress, Nuclear Factor-κB Pathway and Current Smoking in Graves' Ophthalmopathy

in European Thyroid Journal
Authors:
Horea Ioan Ursu ‘C.I. Parhon' National Institute of Endocrinology

Search for other papers by Horea Ioan Ursu in
Current site
Google Scholar
PubMed
Close
and
Monica Livia Gheorghiu ‘Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania

Search for other papers by Monica Livia Gheorghiu in
Current site
Google Scholar
PubMed
Close

*Assoc. Prof. Horea Ioan Ursu, MD, PhD, C.I. Parhon National Institute of Endocrinology, 34-36 Aviatorilor Blvd, sect.1, RO-011863 Bucharest (Romania), E-Mail horeaursu@hotmail.com
Free access

Sign up for journal news

Dear Sir,

Increased generation of reactive oxygen species (ROS) is thought to play a role in the pathogenesis of Graves' ophthalmopathy (GO) [1,2]. Selenium (Se) is an antioxidant agent that has been recently shown to improve significantly the course of mild GO [2]. There is good evidence that oxidative stress plays a role in GO: orbital fibroblasts of GO patients have higher contents of malondialdehyde, superoxide anions and hydrogen peroxide than control orbital fibroblasts [3]. Orbital fibroblasts are recognized as the prime target cells of the autoimmune attack in GO [3].

We suggest a possible interplay between nuclear factor-κB (NF-κB), pro-inflammatory cytokines (which activate and are activated by NF-κB, by amplifying and perpetuating orbital inflammation), ROS, Se and glucocorticoids (GC) (fig. 1) in GO [4,5]. Many of the GC effects are mediated through an inhibition of NF-κB [6] (fig. 1). GC binding to its receptor may have a dual effect on gene activation such as activation of transcription (transactivation) or a suppression of transcription (transrepression) by interacting with NF-κB; consequently, the production of anti-inflammatory proteins is increased (transactivation), whereas the inflammatory ones are diminished (transrepression) [7].

Fig. 1
Fig. 1

Positive regulatory loop of pro-inflammatory cytokines (IL-1 = interleukin-1, TNF-α = tumor necrosis factor-α) and NF-κB regulated by GC, Se and ROS in GO. Cigarette smoking is a major source of ROS.

Citation: European Thyroid Journal 2, 1; 10.1159/000347235

In our view, the decreased efficacy of GC therapy in current smokers [8] might be explained - at least in part - by the antagonism GC - ROS revealed at the NF-κB level [4] (fig. 1). Cigarette smoking is a major source of ROS which are able to stimulate the NF-κB pathway (fig. 1), a cornerstone of immune and inflammatory response [5].

Future studies (immunosuppressive therapy plus Se) in patients with more severe GO are, at least in part, justified by the following data: (a) GC [6,7] and Se [9] seem to have a similar inhibitory (possibly synergistic) effect on NF-κB activity (fig. 1), and (b) opposite effects on the NF-κB pathway of current smoking (stimulatory effect via a prooxidant effect) [5] and Se (inhibitory effect via an antioxidant action) [9] (fig. 1). Therefore, a detailed analysis of the influence of smoking upon any antioxidant therapy in patients with GO would be valuable.

Disclosure Statement

The authors have no conflicts of interest to disclose.

Footnotes

verified

References

  • 1

    Marcocci C, Leo M, Altea MA: Oxidative stress and Graves' disease. Eur Thyroid J 2012;1:80-87.

    • Crossref
    • PubMed
    • Export Citation
  • 2

    Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga WM: Selenium and the course of mild Graves' ophthalmopathy. N Engl J Med 2011;364:1920-1931.

    • Crossref
    • PubMed
    • Export Citation
  • 3

    Wiersinga WM: Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 2011;96:2386-2394.

    • Crossref
    • PubMed
    • Export Citation
  • 4

    Ursu H, Badiu C, Gheorghiu ML: Selenium, mild Graves' ophthalmopathy and current smoking status. Acta Endocrinol (Buc) 2012;8:467-470.

    • PubMed
    • Export Citation
  • 5

    Barnes PJ, Karin M: Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.

    • Crossref
    • PubMed
    • Export Citation
  • 6

    Krassas GE, Heufelder AE: Immunosuppressive therapy in patients with thyroid disease: an overview of current concepts. Eur J Endocrinol 2001;144:311-318.

    • Crossref
    • PubMed
    • Export Citation
  • 7

    Zang S, Ponto KA, Kahaly GJ: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011;96:320-332.

    • Crossref
    • PubMed
    • Export Citation
  • 8

    Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A: Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 1998;129:632-635.

    • PubMed
    • Export Citation
  • 9

    Maehira F, Miyagi I, Eguchi Y: Selenium regulates transcription factor NF-κB activation during the acute phase reaction. Clin Chim Acta 2003;334:163-171.

    • Crossref
    • PubMed
    • Export Citation

 

  • Collapse
  • Expand
  • Fig. 1

    Positive regulatory loop of pro-inflammatory cytokines (IL-1 = interleukin-1, TNF-α = tumor necrosis factor-α) and NF-κB regulated by GC, Se and ROS in GO. Cigarette smoking is a major source of ROS.

  • 1

    Marcocci C, Leo M, Altea MA: Oxidative stress and Graves' disease. Eur Thyroid J 2012;1:80-87.

    • Crossref
    • PubMed
    • Export Citation
  • 2

    Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga WM: Selenium and the course of mild Graves' ophthalmopathy. N Engl J Med 2011;364:1920-1931.

    • Crossref
    • PubMed
    • Export Citation
  • 3

    Wiersinga WM: Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 2011;96:2386-2394.

    • Crossref
    • PubMed
    • Export Citation
  • 4

    Ursu H, Badiu C, Gheorghiu ML: Selenium, mild Graves' ophthalmopathy and current smoking status. Acta Endocrinol (Buc) 2012;8:467-470.

    • PubMed
    • Export Citation
  • 5

    Barnes PJ, Karin M: Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.

    • Crossref
    • PubMed
    • Export Citation
  • 6

    Krassas GE, Heufelder AE: Immunosuppressive therapy in patients with thyroid disease: an overview of current concepts. Eur J Endocrinol 2001;144:311-318.

    • Crossref
    • PubMed
    • Export Citation
  • 7

    Zang S, Ponto KA, Kahaly GJ: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011;96:320-332.

    • Crossref
    • PubMed
    • Export Citation
  • 8

    Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A: Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 1998;129:632-635.

    • PubMed
    • Export Citation
  • 9

    Maehira F, Miyagi I, Eguchi Y: Selenium regulates transcription factor NF-κB activation during the acute phase reaction. Clin Chim Acta 2003;334:163-171.

    • Crossref
    • PubMed
    • Export Citation